What it is
A blend of two compounds acting on different receptors of the growth-hormone axis: CJC-1295 without DAC (Modified GRF 1-29), a GHRH analogue, and Ipamorelin, a selective ghrelin-receptor agonist. The two are frequently combined in research because they act synergistically.
Mechanism
CJC-1295 stimulates the GHRH receptor and increases the amplitude of GH pulses; Ipamorelin acts on the GHS-R1a receptor and increases pulse frequency while suppressing somatostatin. Together they produce a stronger and more physiological GH release than either alone. Ipamorelin is notable for its selectivity: it does not meaningfully raise cortisol, prolactin or ACTH.
Research areas
- Growth-hormone pulsatility
- Body composition and lipolysis
- Recovery and tissue repair via IGF-1
- Sleep architecture
- Bone density models
Safety and metabolism
Both peptides have short half-lives (≈ 30 min for Mod GRF 1-29, ≈ 2 h for Ipamorelin), which is why the GH response stays pulsatile. Ipamorelin is one of the best tolerated GHRPs in the literature.
Why this amount
10 mg + 10 mg in one vial, a 1:1 ratio, is the standard research combination.
